{
  "first_published_at": "2010-04-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087709", 
  "title": "Rifadin infusion (rifampicin): new solvent formulation and changes to compatible diluents", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 205, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Rifadin infusion (rifampicin): new solvent formulation and changes to compatible diluents</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: April 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>The solvent used in the preparation of Rifadin infusion has been reformulated. As a result, it can only be diluted with either dextrose 5% solution or sodium chloride 0&#183;9% solution<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Rifadin 600 mg infusion (rifampicin) is used to treat various infections, including tuberculosis and leprosy. It is indicated for acutely ill patients who are unable to tolerate oral therapy. To prevent emergence of resistant strains, Rifadin should be used in combination with another appropriate antibiotic.</p><h2>New solvent formulation</h2><p>The solvent used in the preparation of Rifadin infusion has been reformulated. As a consequence the diluents which may be used to administer the medicine have changed.</p><p>An animal-derived product, polysorbate 81 (a surfactant), has been removed from the solvent supplied in the pack. This removal is to comply with European Commission requirements to minimise the risk of transmissible spongiform encephalopathy in medicinal products. For this reason, and in view of the limited data available, the diluents that can be used with the reconstituted powder have been restricted to <strong>dextrose 5%</strong> and <strong>normal saline</strong>.</p><p>The new formulation is expected to be available in April 2010. The marketing authorisation holder is taking steps to minimise the amount of time that the two formulations are in the supply chain concurrently. Healthcare professionals should use all existing stock before introducing the reformulated product.</p><p>The carton has been revised to help identify the reformulated product. It is clearly marked: &ldquo;Important update on incompatibilities. Please see Technical Leaflet&rdquo;. A <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452\" target=\"_blank\">letter announcing the reformulation of Rifadin infusion</a> was sent to healthcare professionals in March 2010.</p><p><img border=\"0\" src=\"/idcm2/groups/dsu/documents/websiteresources/con087748.jpg\"></p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Rifadin infusion has been reformulated</li>\r\n\t\t\t\t<li>The new formulation can only be diluted with either dextrose 5% solution or sodium chloride 0&middot;9% solution</li>\r\n\t\t\t\t<li>If you are in doubt about which formulation of Rifadin is in use, contact a hospital pharmacist before reconstitution or administration</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p>See also <a href=\"http://www.medicines.org.uk/EMC/medicine/6435/SPC/Rifadin+For+Infusion+600mg/\" target=\"_blank\">Summary of Product Characteristics</a> for Rifadin infusion.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update April 2010, vol 3 issue 9: 9.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Rifadin 600 mg infusion (rifampicin) is used to treat various infections, including tuberculosis and leprosy. It is indicated for acutely ill patients who are unable to tolerate oral therapy. To prevent emergence of resistant strains, Rifadin should be used in combination with another appropriate antibiotic.</p><h2>New solvent formulation</h2><p>The solvent used in the preparation of Rifadin infusion has been reformulated. As a consequence the diluents which may be used to administer the medicine have changed.</p><p>An animal-derived product, polysorbate 81 (a surfactant), has been removed from the solvent supplied in the pack. This removal is to comply with European Commission requirements to minimise the risk of transmissible spongiform encephalopathy in medicinal products. For this reason, and in view of the limited data available, the diluents that can be used with the reconstituted powder have been restricted to <strong>dextrose 5%</strong> and <strong>normal saline</strong>.</p><p>The new formulation is expected to be available in April 2010. The marketing authorisation holder is taking steps to minimise the amount of time that the two formulations are in the supply chain concurrently. Healthcare professionals should use all existing stock before introducing the reformulated product.</p><p>The carton has been revised to help identify the reformulated product. It is clearly marked: &#8220;Important update on incompatibilities. Please see Technical Leaflet&#8221;. A <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452\" target=\"_blank\">letter announcing the reformulation of Rifadin infusion</a> was sent to healthcare professionals in March 2010.</p><p><img border=\"0\" src=\"http://www.mhra.gov.uk/idcm2/groups/dsu/documents/websiteresources/con087748.jpg\" alt=\"Rifadin 600mg infusion\"></p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Rifadin infusion has been reformulated</li>\r\n\t\t\t\t<li>The new formulation can only be diluted with either dextrose 5% solution or sodium chloride 0&#183;9% solution</li>\r\n\t\t\t\t<li>If you are in doubt about which formulation of Rifadin is in use, contact a hospital pharmacist before reconstitution or administration</li>\r\n\t\t\t</ul></div><p>&#160;</p><p>See also <a href=\"http://www.medicines.org.uk/EMC/medicine/6435/SPC/Rifadin+For+Infusion+600mg/\" target=\"_blank\">Summary of Product Characteristics</a> for Rifadin infusion.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update April 2010, vol 3 issue 9: 9.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-04-01", 
  "date_last_modified": "2010-09-13", 
  "_assets": [
    {
      "content_type": "image/jpeg", 
      "title": "Rifadin 600mg infusion", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/idcm2/groups/dsu/documents/websiteresources/con087748.jpg", 
      "filename": "downloads/3cf7d474e2730e184e48860bac977e5a2c30ee4e/con087748.jpg", 
      "original_filename": "con087748.jpg"
    }
  ], 
  "_item_id": 205, 
  "summary": "The solvent used in the preparation of Rifadin infusion has been reformulated. As a result, it can only be diluted with either dextrose 5% solution or sodium chloride 0Â·9% solution", 
  "body": "Article date: April 2010\n\nRifadin 600 mg infusion (rifampicin) is used to treat various infections, including tuberculosis and leprosy. It is indicated for acutely ill patients who are unable to tolerate oral therapy. To prevent emergence of resistant strains, Rifadin should be used in combination with another appropriate antibiotic.\n\n## New solvent formulation\n\nThe solvent used in the preparation of Rifadin infusion has been reformulated. As a consequence the diluents which may be used to administer the medicine have changed.\n\nAn animal-derived product, polysorbate 81 (a surfactant), has been removed from the solvent supplied in the pack. This removal is to comply with European Commission requirements to minimise the risk of transmissible spongiform encephalopathy in medicinal products. For this reason, and in view of the limited data available, the diluents that can be used with the reconstituted powder have been restricted to dextrose 5% and normal saline.\n\nThe new formulation is expected to be available in April 2010. The marketing authorisation holder is taking steps to minimise the amount of time that the two formulations are in the supply chain concurrently. Healthcare professionals should use all existing stock before introducing the reformulated product.\n\nThe carton has been revised to help identify the reformulated product. It is clearly marked: âImportant update on incompatibilities. Please see Technical Leafletâ. A [letter announcing the reformulation of Rifadin infusion](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON076452) was sent to healthcare professionals in March 2010.\n\n![ASSET_TAG](#ASSET0)\n\nAdvice for healthcare professionals:  \n  \n  * Rifadin infusion has been reformulated  \n  * The new formulation can only be diluted with either dextrose 5% solution or sodium chloride 0Â·9% solution  \n  * If you are in doubt about which formulation of Rifadin is in use, contact a hospital pharmacist before reconstitution or administration  \n  \nÂ \n\nSee also [Summary of Product Characteristics](http://www.medicines.org.uk/EMC/medicine/6435/SPC/Rifadin+For+Infusion+600mg/) for Rifadin infusion.\n\nÂ \n\nArticle citation: Drug Safety Update April 2010, vol 3 issue 9: 9.\n"
}